SRx Health Solutions Announces Board and Executive Changes
Ticker: SRXH · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1471727
Sentiment: neutral
Topics: management-change, compensation, board-of-directors
TL;DR
SRx Health Solutions shakes up board and exec pay - new faces, new plans.
AI Summary
SRx Health Solutions, Inc. announced on October 1, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans. Specific details regarding the individuals involved and the financial implications of these changes are outlined within the report.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation structures can introduce uncertainty and potential strategic shifts, warranting closer investor scrutiny.
Key Players & Entities
- SRx Health Solutions, Inc. (company) — Registrant
- October 1, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-40477 (commission_file_number) — SEC File Number
- 83-4284557 (ein) — IRS Employer Identification No.
- 12400 Race Track Road (address) — Business Address
- Tampa (city) — Business Address City
- Florida (state) — Business Address State
- 33626 (zip_code) — Business Address Zip
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates departures of certain officers and directors, but the specific roles are detailed within the report's sections on Item 5.02.
Who are the newly elected directors of SRx Health Solutions, Inc.?
The election of new directors is reported under Item 5.02 of the 8-K filing.
What are the key changes in the compensatory arrangements for certain officers?
The filing addresses updates to compensatory arrangements for certain officers, with specific details provided in the relevant sections of the report.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 1, 2025.
What is the primary business of SRx Health Solutions, Inc. according to its SIC code?
According to its Standard Industrial Classification (SIC) code, SRx Health Solutions, Inc. is in the BEVERAGES industry [2080].
Filing Stats: 749 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2025-10-06 14:02:59
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value share SRXH NYSE American
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex99-1.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-25-017043.txt ( ) — 222KB
- srxh-20251001.xsd (EX-101.SCH) — 3KB
- srxh-20251001_lab.xml (EX-101.LAB) — 33KB
- srxh-20251001_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 1, 2025 SRx Health Solutions, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40477 83-4284557 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 12400 Race Track Road Tampa , Florida 33626 (Address of Principal Executive Offices) (Zip Code) (Registrant's Telephone Number, Including Area Code): ( 212 ) 896-1254 N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value share SRXH NYSE American Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Joshua A. Epstein as a Director On October 1, 2025, the Board of Directors (the "Board") of SRx Health Solutions, Inc., a Delaware corporation (the "Company") appointed Joshua A. Epstein, as a director of the Company, effective immediately, to serve in such capacity until a successor has been elected and qualified, or until his resignation or removal. Mr. Epstein has over 20 years of operational, advisory and investing experience in the energy, technology, healthcare, medical cannabis, blockchain, and gaming sectors, including as an executive, investor, and attorney. Since December of 2024, Mr. Epstein has been the head of Corporate Development and on the Board of Managers for for Lisbon Valley Mining Co., overseeing all capital markets, M&A, partnership, and other transactional activities for the producing copper mine in Southeast Utah. Formerly, from March 2021 to November 2024, Mr. Epstein was a consultant to JJR Private Capital, a Florida and Toronto-based private equity firm founded in 2003. Previously, Mr. Epstein served as the CEO and Director of Socati Corp., a vertically integrated manufacturer of ingredients and consumer products for global cannabinoid and wellness markets. Prior to Socati, Mr. Epstein served as President and COO of Nuuvera Inc., an international wellness and medical cannabis company founded in 2016 that later listed on the Toronto Stock Exchange–V and sold to Tilray Inc. (NASDAQ: TLRY) (formerly Aphria Inc.) in 2018. Mr. Epstein was previously a Partner with FastForward Innovations Ltd., an early-stage venture capital firm where he oversaw investments and divestitures of the firm's portfolio companies in the United States, Canada, the United Kingdom, Germany, Israel and China. Mr. Epstein began his career as an attorney with the international law firm Baker Botts, LLP, where his practice focused on mergers and acquisitions, venture capital and securities offerings. Mr. Epstein holds a B.A (English, Honors Program) and B.B.A. (Finance) from the University of Texas, a JD from the University of Texas School of Law, where he graduated with Honors and as a member of the Texas Law Review, and an MBA from the Acton School of Business in Austin, Texas, where he was Valedictorian of his class. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 1, 2025. 104 Cover Page Interactive Data File (Embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SRx Health Solutions, Inc. By: /s/ Carolina Martinez Name: Carolina Martinez Title: Chief Financial Officer October 6, 202